- Home
- SNES vs CMMB Comparison
SNES vs CMMB Comparison
Compare SNES & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNES | CMMB |
|---|---|---|
| Founded | 2004 | 2004 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.5M | 13.8M |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | SNES | CMMB |
|---|---|---|
| Price | $2.33 | $1.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $26.50 |
| AVG Volume (30 Days) | 36.9K | ★ 97.8K |
| Earning Date | 11-10-2025 | 11-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,301,000.00 | N/A |
| Revenue This Year | $41.52 | N/A |
| Revenue Next Year | $77.28 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 39.37 | N/A |
| 52 Week Low | $1.30 | $1.73 |
| 52 Week High | $6.24 | $9.84 |
Technical Indicators
Market Signals| Indicator | SNES | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 36.89 | 28.76 |
| Support Level | $2.25 | $1.73 |
| Resistance Level | $2.53 | $2.24 |
| Average True Range (ATR) | 0.19 | 0.27 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 12.50 | 14.42 |
Price Performance
Historical ComparisonAbout SNES SenesTech Inc.
SenesTech Inc is a United States-based biotech platform and research company engaged in developing technology for managing animal pest populations through fertility control. The company provides its solutions to the animal market, commercial markets, and food markets. It currently has two product lines of fertility control products: ContraPest and Evolve.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.